Clinical trial NCT02461537: Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
Official title: Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acute Myeloid Leukemia
Lead sponsor: DKMS gemeinnützige GmbH
Sponsor class: OTHER
First posted: 2015-06-03
Enrollment: 281
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial compares outcome of two treatment strategies for patients with high-risk AML who failed to achieve or maintain a complete remission with standard therapy. Patients will be randomized between two strategies. The standard strategy is aimed at achieving a complete remission by aggressive salvage chemotherapy using high dose cytarabine and mitoxantrone, . The alternative is a less toxic disease-control strategy of disease monitoring and, if necessary, low-dose cytarabine or mitoxantrone prior to allogeneic transplantation, which should be performed as soon as possible.

Detailed description: Patients with high-risk acute myeloid leukemia (AML) who relapsed or showed a poor response to induction chemotherapy have a dismal prognosis. For these patients, allogeneic transplantation is the recommended treatment. While allogeneic transplantation may be considered as the ultimate treatment concept, the treatment path to transplantation is not well defined.

The traditional approach to pursue a complete remission by means of aggressive reinduction chemotherapy prior to allogeneic transplantation. This approach is associated with potentially life-threatening toxicities and has limited efficacy. As a result, only some patients will reach allogeneic transplantation in complete remission.

To reduce the number of patients who die or who are ineligible for transplantation due to the toxicity of aggressive induction chemotherapy, other bridging options have been explored. One promising alternative is to abstain from remission induction. Instead, disease control by means of less aggressive chemotherapy or simply monitoring leukemic proliferation can be considered.

This randomized trial will identify if there is non-inferiority of the less toxic approach, compared to the standard approach of remission induction by aggressive chemotherapy prior to allogeneic transplantation.

Eligibility criteria: Inclusion Criteria

* Signed written informed consent.
* Male and female patients of 18 to 75 years of age.
* Diagnosis of AML according to WHO criteria.
* Patient is fit for aggressive induction chemotherapy and transplantation by assessment of an experienced hematologist.
* No history of chronic pulmonary disease and absence of dyspnea. Otherwise, documented diffusion lung capacity for carbon monoxide ( DLCO ) ≤ 40 percent ( adjusted for hemoglobin, if available ) and FEV1 / FVC ≥ 50 percent.
* HLA - identical sibling. or
* HLA - compatible unrelated donor ( ≥ 9 /10 antigens matched for HLA - A, - B, - C, -DRB 1, and - DQB 1 ) with completed confirmatory typing or
* Two unrelated donors with \> 90 percent probability of a 9 /10 match for HLA - A, - B, - C, - DRB 1, and - DRQB 1, according to Opti Match ® list.

For the relapse stratum

* First AML relapse, defined as ≥ 5 percent bone marrow blasts and / or extramedullary AML manifestation.

For the poor - responders stratum

* AML that evolves from previously documented myelodysplastic syndrome ( MDS ),

and / or

* diagnosis of therapy-related myeloid neoplasm ( t - MN ), and / or

a ) If patient ≤ 60 years old adverse risk AML according to ELN - criteria and ≥ 5 percent bone marrow blasts after the first cycle of induction therapy.

b ) If patient \> 60 years old non-favourable risk AML according to ELN - criteria and ≥ 5 percent bone marrow blasts after the first cycle of induction therapy.

Exclusion Criteria

* Acute promyelocytic leukemia ( APL ).
* WBC count of ≥ 50 GPt / L at study inclusion.
* For patients in the poor - responder stratum the first cycle of induction therapy must not contain HDAC, defined as cytarabine at single-doses of \> 1 g / m 2.
* Patient has received more than 440 mg / m2 daunorubicin equivalents.
* Severe organ dysfunction, defined as
* Left ventricular ejection fraction \< 50 percent.
* Patients who receive supplementary continuous oxygen.
* Serum bilirubin \> 1.5 x ULN ( if not considered Gilbert-Syndrome ), ASAT / ALAT \> 5 x ULN.
* Estimated GFR \< 50 ml / min.
* Treatment with any investigational drug within 10 days before study entry.
* Uncontrolled infection at the time of enrollment.
* History of allogeneic transplantation.
* Manifestation of AML in the central nervous system.
* Pregnant or breast - feeding women.
* Men unable or unwilling to use adequate contraception methods from start of study treatment to minimum of six months after the last dose of chemotherapy.
* Women of childbearing potential except those who fulfill the following criteria: Post-menopausal or post-operative or continuous and correct application of a contraception method with a Pearl Index \< 1 percent or sexual abstinence or vasectomy of the sexual partner.

Primary outcomes:
measure: Disease-free survival
timeFrame: on day 56 after allogeneic SCT
Secondary outcomes:
measure: Overall survival
timeFrame: 4 weeks, 8 weeks, and 24 weeks from randomization
measure: Rate of allogeneic transplantation
timeFrame: 4 weeks, 8 weeks, and 16 weeks from randomization
measure: Incidence of CR
timeFrame: at 4 weeks, 8 weeks, and 24 weeks from randomization
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Universitätsklinikum Heidelberg
state: Baden-Wuerttemberg
city: Mannheim
country: Germany
facility: Universitätsmedizin Mannheim
state: Baden-Wuerttemberg
city: Stuttgart
country: Germany
facility: Robert-Bosch-Krankenhaus
state: Baden-Wuerttemberg
city: Tübingen
country: Germany
facility: Universitätsklinikum Tübingen
state: Baden-Württemberg
city: Winnenden
country: Germany
facility: Rems-Murr-Kliniken gGmbH
state: Baden-Württemberg
city: Augsburg
country: Germany
facility: Klinikum Augsburg
state: Bavaria
city: Erlangen
country: Germany
facility: Universitätsklinikum Erlangen
state: Bavaria
city: Nürnberg
country: Germany
facility: Klinikum Nürnberg Nord
state: Bavaria
city: Frankfurt am Main
country: Germany
facility: Universitätsklinikum Frankfurt
state: Hessen
city: Aachen
country: Germany
facility: Universitätsklinikum Aachen, AÖR
state: Nordrhein-Westphalen
city: Essen
country: Germany
facility: Universitätsklinikum Essen (AöR)
state: Nordrhein-Westphalen
city: Münster
country: Germany
facility: Universitätsklinikum Münster
state: North Rhine-Westphalia
city: Mainz
country: Germany
facility: Universitätsmedizin der Johannes Gutenberg-Universität Mainz
state: Rhineland-Palatinate
city: Halle
country: Germany
facility: Universitätsklinikum Halle (Saale)
state: Saxony-Anhalt
city: Dresden
country: Germany
facility: University Hospital
state: Saxony
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig
state: Saxony
city: Riesa
country: Germany
facility: Elblandkliniken Stiftung & Co. KG
state: Saxony
city: Berlin
country: Germany
facility: Helios Klinikum Berlin Buch
Study officials:
affiliation: Universtitätsklinikum Dresden
name: Johannes Schetelig, Prof Dr med
role: STUDY_CHAIR
References: